Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical s (Q50546615)

From Wikidata

Jump to navigation Jump to search

scientific article published on 5 February 2011

Language	Label	Description	Also known as
English	Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical s	scientific article published on 5 February 2011

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical s (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

1 reference

based on heuristic

inferred from title

author name string

Tatsuo Furukawa

1

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Miwako Narita

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Tadashi Koike

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Kazue Takai

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Koichi Nagai

5

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Masashi Kobayashi

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Satoru Koyama

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Yoshinobu Seki

8

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Hoyu Takahashi

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Masahiro Fujiwara

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Kenji Kishi

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Koji Nikkuni

12

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Noriatsu Isahai

13

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Wataru Higuchi

14

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Nobuhiko Nomoto

15

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Souichi Maruyama

16

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Masayoshi Masuko

17

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Takashi Kuroha

18

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Takashi Abe

19

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Ken Toba

20

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Masuhiro Takahashi

21

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Yoshifusa Aizawa

22

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Akira Shibata

23

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

publication date

5 February 2011

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

International Journal of Hematology

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

93

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

336-343

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

https://scigraph.springernature.com/pub.10.1007/s12185-011-0774-2

0 references

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Monitoring treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1007%2FS12185-011-0774-2

21 January 2018

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21293953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Milestones and monitoring in patients with CML treated with imatinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/21293953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/21293953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initial treatment for patients with CML.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21293953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21293953

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12185-011-0774-2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/21293953

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50546615&oldid=1584538990"